Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT

31 oktober 2026 uppdaterad av: Xiao-Jun Huang, Peking University People's Hospital

Busulfan Based Versus Total Body Irradiation Based for Adults Acute B Lymphoblastic Leukemia in CR2: An Multicenter, Non-Inferiority Study

This is an multicenter, non-inferiority randomized controlled trial. Adult patients (14-65 years) with acute lymphoblastic leukemia in second complete remission (CR2) scheduled for allogeneic hematopoietic stem-cell transplantation (allo-HSCT) will be randomized 1:1 to receive either busulfan-based chemotherapy-only conditioning (experimental arm) or total-body-irradiation (TBI)-based conditioning (active comparator arm). The primary objective is to test the non-inferiority of chemotherapy-based conditioning versus TBI-based conditioning regarding 1-year leukemia-free survival (LFS). Secondary endpoints include treatment-related mortality (TRM), cumulative incidence of relapse (CIR), graft-versus-host-disease (GVHD), and overall survival (OS). All patients receive uniform GVHD prophylaxis and post-transplant supportive care.

Studieöversikt

Detaljerad beskrivning

Adult ALL patients achieving second complete remission (CR2) represent a high-risk population for relapse after allo-HSCT. Allo-HSCT is the standard curative therapy, yet optimal preparative conditioning remains controversial. Most published evidence focuses on CR1 ALL patients; prospective head-to-head comparison between chemotherapy-only and TBI-based conditioning specifically for adult CR2 ALL is scarce and mainly relies on retrospective cohorts. While TBI-based conditioning provides favorable anti-leukemia effect, it carries substantial acute and late toxicities. Chemotherapy-only conditioning may reduce radiation-related toxicities but raises concern for higher relapse risk. This multicenter randomized phase III non-inferiority trial aims to provide prospective evidence to guide conditioning-regimen selection for adult ALL-CR2 patients undergoing allo-HSCT.

Eligible subjects are randomly assigned 1:1 via central stratified block randomization (variable block sizes:4,6,8). Investigators and participants are not blinded to treatment assignment; outcome assessment and statistical analysis are performed in a blinded fashion.

Experimental Arm (Busulfan-based chemotherapy-only conditioning): Busulfan 0.8 mg/kg q.i.d. day -8 to -6; cyclophosphamide 1.8 g/m²/day day -5, -4; semustine 250 mg/m² day -3. For haploidentical transplant recipients: rabbit-ATG 2.5 mg/kg/day day -5 to -2.

Active Comparator Arm (TBI-based conditioning): Total-body irradiation 770 cGy on day -6; cyclophosphamide 1.8 g/m²/day day -5, -4; semustine 250 mg/m² day -3. For haploidentical transplant recipients: rabbit-ATG 2.5 mg/kg/day day -5 to -2.

Grafts consist of G-CSF-mobilized bone marrow plus peripheral-blood stem cells. Uniform post-transplant GVHD prophylaxis includes cyclosporine-A, mycophenolate mofetil, and short-course methotrexate.

Planned follow-up time-points: +1, +2, +3, +4.5, +6, +9, +12, +18, +24, +36, +48, +60 months post-transplant. Assessments include bone-marrow morphology, multiparameter flow MRD, molecular MRD (fusion gene / Ig-TCR / NGS), chimerism analysis, complete blood count, biochemistry, virology screening, and GVHD evaluation per NIH consensus criteria.

Studietyp

Interventionell

Inskrivning (Beräknad)

180

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Beijing, Kina
        • Peking University People's Hospital, Beijing Lu Daopei Hematology Hospital, Hebei Yanda Lu Daopei Hospital, Nanfang Hospital, Southern Medical University
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

14 år till 65 år (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Age ≥ 14 and ≤ 65 years (inclusive).
  2. Diagnosis of acute lymphoblastic leukemia according to NCCN diagnostic criteria.
  3. Confirmed second complete remission (CR2) before allogeneic hematopoietic stem-cell transplantation.
  4. Planned to undergo allo-HSCT.
  5. ECOG performance status < 3.
  6. Written informed consent obtained.

Exclusion Criteria:

  1. Diagnosis of acute biphenotypic leukemia.

  2. Uncontrolled active infection at screening.

  3. Significant organ dysfunction:

    • Liver: ALT/AST > 3.0 × ULN and/or total bilirubin > 1.5 × ULN; severe cirrhosis, portal hypertension or active liver disease.
    • Renal: eGFR < 60 mL/min/1.73 m² by CKD-EPI formula or serum creatinine > 1.5 × ULN; regular dialysis requirement.
    • Cardiac: NYHA class III-IV heart failure; unstable angina / myocardial infarction / coronary revascularization within prior 6 months; LVEF < 50 %; clinically significant uncontrolled arrhythmia.
    • Pulmonary: chronic lung disease requiring long-term oxygen therapy; resting SpO₂ < 92 % (room-air).
  4. Participation in another investigational drug trial within past 3 months.

  5. Psychiatric disorders interfering with protocol compliance.

  6. History of other malignant neoplasms within 2 years prior to screening.

  7. Any condition judged by investigator rendering subject unsuitable for trial participation.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Chemotherapy-only Conditioning Regimen

intervention: Drug: Busulfan: 0.8 mg/kg intravenous, four times daily, day -8 to day -6 Drug: Cyclophosphamide: 1.8 g/m²/day intravenous, day -5, day -4 Drug: Semustine: 250 mg/m² oral, day -3 Drug: Rabbit anti-thymocyte globulin (ATG): 2.5 mg/kg/day intravenous day -5 to -2 (only for haploidentical transplant recipients) All subjects receive identical post-transplant GVHD-prophylaxis: cyclosporine-A, mycophenolate mofetil, short-course methotrexate; standard supportive care.

Experimental Arm (Chemotherapy-based conditioning): Busulfan 0.8 mg/kg q.i.d. day -8 to -6; cyclophosphamide 1.8 g/m²/day day -5, -4; semustine 250 mg/m² day -3. For haploidentical transplant recipients: rabbit-ATG 2.5 mg/kg/day day -5 to -2.

Aktiv komparator: TBI-based Conditioning Regimen

intervention Radiation: Total-Body Irradiation (TBI): 770 cGy administered on day -6 Drug: Cyclophosphamide: 1.8 g/m²/day intravenous, day -5, day -4 Drug: Semustine: 250 mg/m² oral, day -3 Drug: Rabbit anti-thymocyte globulin (ATG): 2.5 mg/kg/day intravenous day -5 to -2 (only for haploidentical transplant recipients) All subjects receive identical post-transplant GVHD-prophylaxis: cyclosporine-A, mycophenolate mofetil, short-course methotrexate; standard supportive care.

Active Comparator Arm (TBI-based conditioning): Total-body irradiation 770 cGy on day -6; cyclophosphamide 1.8 g/m²/day day -5, -4; semustine 250 mg/m² day -3. For haploidentical transplant recipients: rabbit-ATG 2.5 mg/kg/day day -5 to -2.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
1-Year Leukemia-Free Survival (LFS)
Tidsram: 12 months post-hematopoietic stem-cell infusion]

Time from stem-cell infusion to leukemia relapse or death from any cause, whichever occurs first.

12 months post-hematopoietic stem-cell infusion]

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
1-Year Treatment-Related Mortality (TRM)
Tidsram: 12 months post-transplantation

Cumulative incidence of non-relapse-related death after transplantation (competing risk: leukemia relapse).

12 months post-transplantation
Cumulative Incidence of Relapse (CIR)
Tidsram: 1-year, 2-year, 3-year post-transplantation

Cumulative probability of hematologic or molecular leukemia relapse with death as competing risk event.

1-year, 2-year, 3-year post-transplantation
Cumulative Incidence of Acute and Chronic Graft-Versus-Host Disease (GVHD)
Tidsram: Day 100, 1-year, 3-year post-transplantation

Cumulative incidence of grade II-IV, grade III-IV acute GVHD (100-day landmark); cumulative incidence of mild/moderate/severe chronic GVHD within 3 years, graded according to NIH GVHD consensus criteria.

Day 100, 1-year, 3-year post-transplantation
Overall Survival (OS)
Tidsram: 1-year, 2-year, 3-year post-transplantation

Time from stem-cell infusion until death from any cause.

1-year, 2-year, 3-year post-transplantation
Conditioning-related organ toxicities
Tidsram: Conditioning start up to post-transplant day +30

Incidence of grade 1-4 cardiac, hepatic, renal, gastrointestinal and mucosal toxicities from conditioning initiation up to day +30 post-transplantation, graded by WHO organ-toxicity scale.

Conditioning start up to post-transplant day +30
Hematopoietic engraftment
Tidsram: Day 30 and Day 90 post-transplantation

Neutrophil engraftment: sustained ANC ≥ 0.5 × 10⁹/L for three consecutive days; platelet engraftment: sustained PLT ≥ 20 × 10⁹/L without transfusion support for seven consecutive days.

Day 30 and Day 90 post-transplantation
Molecular/Flow-MRD status post-transplant
Tidsram: +1, +2, +3, +6, +12 months post-transplantation

MRD positive defined as flow cytometry ≥ 0.01 %; or detectable quantifiable fusion-gene / Ig-TCR / NGS clonal signal above assay sensitivity threshold at serial follow-up time-points.

+1, +2, +3, +6, +12 months post-transplantation

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Xiao-Jun Huang, Peking University Institute of Hematology

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 november 2026

Primärt slutförande (Beräknad)

1 november 2028

Avslutad studie (Beräknad)

30 december 2029

Studieregistreringsdatum

Först inskickad

31 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

31 oktober 2026

Första postat (Faktisk)

5 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

31 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera